USA flag logo/image

An Official Website of the United States Government

Sandwich ELISA using rabbit monoclonal antibodies for liver-stage malaria…

Award Information

Department of Defense
Award ID:
Program Year/Program:
2003 / SBIR
Agency Tracking Number:
Solicitation Year:
Solicitation Topic Code:
Solicitation Number:
Small Business Information
Epitomics, Inc.
Epitomics, Inc. 863 Mitten Rd, Ste 103 Burlingame, CA 94010-0131
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Phase 1
Fiscal Year: 2003
Title: Sandwich ELISA using rabbit monoclonal antibodies for liver-stage malaria detection
Agency / Branch: DOD / ARMY
Contract: DAMD17-03-C-004
Award Amount: $69,888.00


Malaria is a major health problem worldwide, and its significance may be on the increase due to the rapid spread of parasite strains that are resistant to conventional anti-malaria drugs. Evidence suggests that during the inital phase of infection(liver-stage) the Plasmodium parasites may be susceptible to neutralization by drugs or vaccines. The infection of liver cells by plasmodium can be studied in vitro, using human hepatoma cell lines. This system could be used as a model to screen forneutralizing activity. However, this approach is hampered by the lack of a rapid quantitative assay for the number of plasmodium parasites that are present in a hepatoma cell culture. We propose to develop a novel sandwich ELISA assay that will facilitatethe rapid high-throughput screening of anti-malaria drugs. To this end, we will first raise novel rabbit monoclonal antibodies to several major proteins that are present in liver-stage plasmodium parasites. We will use our proprietary rabbit hybridomatechnology to develop antibodies to both synthetic peptides and recombinant proteins based on Plasmodium sequences. Pairs of antibodies recognizing independent epitopes on a given protein will be rapidly identified by using a novel sandwich screeningapproach. This research is designed to develop a rapid ELISA assay for quantifying malaria parasites present in infected liver cells. This novel assay will be substantailly more sensitive, specific, reliable, and easier to use than currently available assays. Itwill provide significant advantages to researchers developing novel approaches for the treatment of liver-stage malaria. On the basis of our novel assay, we will develop a test kit that will be marketed to research institutes, hospitals, and companiesinterested in quantifying infection by liver-stage plasmodium parasites. Furthermore, the novel monoclonal antibodies developed in the course of this project may have additional applications in malaria research and/or drug development.

Principal Investigator:

Robert Pytela
Chief Scientific Officer

Business Contact:

Guoliang Yu
Small Business Information at Submission:

1015 Grandview Drive South San Francisco, CA 94080

EIN/Tax ID: 943409030
Number of Employees:
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No